“FIRST IN CLASS” DRUG LEADS



ProtAgonists developed a technological platform that is unique and innovative. Proprietary, company-owned technologies give ProtAgonists unprecedented advantages in the discovery, production, validation and optimization of drug leads.



ProtAgonists developed an algorithm for the rational identification of drug leads. The company's Interactive Sequence Processor (ISP) identifies and defines short protein sequences, "peptides", that are potential therapeutic modulators of disease-related proteins. 14 (45%) of 31 algorithm-generated compounds have already been shown to have therapeutic activity in animal models of disease



- DISEASE MODULATORS ProtAgonists' Drug Leads are designed to modulate disease-related proteins, without negating them. Modulators of disease-related proteins are designed to be therapeutic with minimal side effects.



- LOW TOXICITY BIOLOGICAL DRUGS ProtAgonists' Drug Leads belong to the new generation of biological drugs, reagents that are well tolerated by the body. The toxic load of a biological reagent is significantly less than that of any synthetic counterpart.